{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0500","upperLimit":".750","value":"0.500"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"}],"units":"Participants"}],"description":"Time to maximum plasma concentration (Tmax) of plerixafor following daily doses of 240 µg/kg plerixafor, determined directly from the concentration-time data","dispersionType":"Full Range","groups":[{"description":"Participants in the pharmacokinetic (PK) subpopulation that offered blood samples for PK analysis. Participants were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 7 aphereses or until ≥ 2\\*10\\^6 CD34+ cells/kg were collected.","id":"OG000","title":"PK Subpopulation"}],"paramType":"MEDIAN","populationDescription":"Participants who provided blood samples for pharmacokinetic (PK) analysis.","reportingStatus":"POSTED","timeFrame":"Day 4 (following first plerixafor administration)","title":"Time to Maximum Plasma Concentration (Tmax) on Day 4","type":"SECONDARY","unitOfMeasure":"Hours"}